← Back to catalogue
Research draft

macular degeneration

vr.tr.macular-degeneration · XCT.STA

Let an agent explain macular degeneration and its forms in general terms from clinical guidelines, relay risk factors, diagnosis and treatment approaches, distinguish age-related from inherited forms, and route personal eye questions to eye care professionals.

Thing Registry Cross-cutting context

Research draft, second pass

A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.

written by Claude from model knowledge without web access - no source was read, every claim is a lead to verify

Researched by: Claude

Purpose and description

Let an agent explain macular degeneration and its forms in general terms from clinical guidelines, relay risk factors, diagnosis and treatment approaches, distinguish age-related from inherited forms, and route personal eye questions to eye care professionals.

A group of eye conditions in which the macula, the central part of the retina responsible for sharp vision, deteriorates, chiefly age-related macular degeneration in dry form progressing to geographic atrophy and wet form with abnormal blood vessels, and inherited macular dystrophies such as Best vitelliform dystrophy and other bestrophinopathies, pattern dystrophies and occult macular dystrophy; macular degeneration is a leading cause of vision loss in older people and is managed with monitoring, injections for wet forms, supplements and low vision support.

What it is for: Not applicable; a group of eye conditions.

It can be explain forms and causes; relay diagnosis and treatment approaches; distinguish age-related from inherited forms; route personal questions.

Distinguishing features

Central vision loss

Age-related and inherited forms

Anti-VEGF treatment for wet AMD

Preserved peripheral vision

What it looks like

Not a visible object; retinal changes seen on examination and imaging.

Physical character

people with AMD worldwide: about 200 million people - estimates

share of AMD that is wet: about 10-15 percent

How it is recognised

Deterioration of the central retina

Dry and wet age-related forms, geographic atrophy, inherited dystrophies

Glaucoma affects the optic nerve; cataract affects the lens; diabetic retinopathy is vascular

Related models

is a kind of - in registry terms

maculopathy

is a kind of - in registry terms

retinal degeneration

is a kind of - in registry terms, as a cause of vision loss

blindness

is treated with - in wet forms

anti-VEGF therapy

In practice

Families and kinds

dry age-related macular degeneration

geographic atrophy

wet or neovascular age-related macular degeneration

Best disease and other bestrophinopathies

vitelliform and pattern macular dystrophies

occult macular dystrophy

myopic macular degeneration

Identifiers

ICD-11 9B75 degeneration of macula and posterior pole

MeSH D008268 macular degeneration

Standards and regulation

Ophthalmology guidelines on AMD management

Approval of anti-VEGF and complement inhibitor therapies

Low vision and disability support rules

Failure modes and hazards

Delayed treatment of wet AMD

Agents giving personal medical advice

Confusing forms

Unproven supplements

Also called

degeneration of macula and posterior poleoccult macular dystrophybestrophinopathypatterned macular dystrophygeographic atrophyvitelliform macular dystrophyKuhnt-Junius degenerationhole retinal cystcystoid macular retinal degenerationtoxic maculopathyBest’s vitelliform macular dystrophymacular dystrophy, vitelliform, 1adult-onset foveomacular vitelliform dystrophymacular dystrophy, vitelliform, 4macular dystrophy, vitelliform, 5macular dystrophy, vitelliform, 3

Where this came from

wikidata · CC0 1.0

Also registered as vr.tr.macular-degeneration

Drafted structure

Bundle to layer to finding to question, as the second pass will find it: 4 bundles · 8 layers · 8 findings · 16 questions.

Help Getting help first.

Safety.

Urgent

Urgent signs.

Urgent

Urgent.

  1. What sudden vision changes need urgent eye care? action
  2. Is the user describing sudden distortion or loss of vision, which needs prompt eye care? boundary

Care

Eye care.

Care

Care.

  1. How is macular degeneration diagnosed and monitored by eye care professionals, in general terms? provenance
  2. Is the user asking about their own eyes, which needs an eye care professional? boundary
Understand The conditions.

Clinical.

Forms

Forms and causes.

Forms

Forms.

  1. What forms of macular degeneration exist, and what causes them? definition
  2. Is the question about age-related or inherited macular degeneration? boundary

Risk

Risk factors.

Risk

Risk.

  1. What risk factors, including age, smoking and genetics, does research identify? provenance
  2. Which entry fits the specific form? action
Treat Treatment and living.

Clinical.

Treatment

Treatment.

Treatment

Treatment.

  1. What treatments exist for wet and dry forms, per guidelines, in general terms? provenance
  2. Which references are standard? provenance

Living

Living with vision loss.

Living

Living.

  1. What low vision aids and support services exist? provenance
  2. Which entry fits low vision rehabilitation? action
Context Research and epidemiology.

Context.

Research

Research.

Research

Research.

  1. What research is ongoing on gene therapy, complement inhibition and cell therapy, with findings attributed? provenance
  2. Which sources are cited? provenance

Epidemiology

Epidemiology.

Epidemiology

Epidemiology.

  1. How common is macular degeneration, and how is prevalence changing, with sources? measurement
  2. Which entry fits global vision loss? action

What the second pass must settle

  • Should age-related macular degeneration be a separate primary entry?
  • How should guidelines be linked?
  • The registry entry has merged aliases naming inherited dystrophies and classifications; should they be split off?